Catalyst Biosciences logo

Catalyst Biosciences Funding & Investors

Catalyst Biosciences, Inc. operates as a biopharmaceutical company. The Company develops novel medicines to address hematology indications, as well as deals in treatment of hemophilia and surgical bleeding. Catalyst Biosciences serves patients in the United States.

catalystbiosciences.com

Total Amount Raised: $301,314,496

Catalyst Biosciences Funding Rounds

  • Post Ipo Equity

    $50,000,000

  • Post Ipo Debt

    $1,000,000

  • Post Ipo Equity

    $5,072,000

    Post Ipo Equity Investors

    Novartis Venture Fund
    Johnson & Johnson Development
    Burrill & Company
    Healthcare Ventures
    Morgenthaler
    Essex Woodlands
  • Post Ipo Equity

    $3,224,993

  • Post Ipo Equity

    $5,009,841

  • Post Ipo Equity

    $400,004

  • Post Ipo Equity

    $5,072,000

    Post Ipo Equity Investors

    Novartis Venture Fund
    Johnson & Johnson Development
    Burrill & Company
    Healthcare Ventures
    Morgenthaler
    Essex Woodlands
  • Post Ipo Equity

    $50,000,000

  • Post Ipo Debt

    $1,000,000

  • Post Ipo Equity

    $3,224,993

  • Post Ipo Equity

    $5,009,841

  • Post Ipo Equity

    $400,004

  • Post Ipo Equity

    $13,407,658

    Post Ipo Equity Investors

    Johnson & Johnson Development
    Burrill & Company
    Sofinnova
    Morgenthaler
    Essex Woodlands
  • Post Ipo Equity

    $13,407,658

    Post Ipo Equity Investors

    Johnson & Johnson Development
    Burrill & Company
    Sofinnova
    Morgenthaler
    Essex Woodlands
  • Post Ipo Equity

    $40,000,000

    Post Ipo Equity Investors

    Novartis Venture Fund
    Johnson & Johnson Development
    Burrill & Company
    Healthcare Ventures
    Sofinnova
    Morgenthaler
    Essex Woodlands
  • Post Ipo Equity

    $7,000,000

  • Post Ipo Equity

    $40,000,000

    Post Ipo Equity Investors

    Novartis Venture Fund
    Johnson & Johnson Development
    Burrill & Company
    Healthcare Ventures
    Sofinnova
    Morgenthaler
    Essex Woodlands
  • Post Ipo Equity

    $7,000,000

  • Series A

    $10,200,000

    Series A Investors

    RCT BioVentures
    Sofinnova
  • Series B

    $30,000,000

    Series B Investors

    Novartis Venture Fund
    Burrill & Company
    RCT BioVentures
    Healthcare Ventures
    Sofinnova
    Morgenthaler
  • Series Unknown

    $60,000,000

    Series Unknown Investors

    Cogene Ventures
    Oxford Bioscience Partners
    Jafco Life Science
    Bison Capital
    Castle Rock Innovations
  • Series A

    $10,200,000

    Series A Investors

    RCT BioVentures
    Sofinnova
  • Series Unknown

    $30,000,000

  • Series B

    $30,000,000

    Series B Investors

    Novartis Venture Fund
    Burrill & Company
    RCT BioVentures
    Healthcare Ventures
    Sofinnova
    Morgenthaler
  • Series Unknown

    $60,000,000

    Series Unknown Investors

    Cogene Ventures
    Oxford Bioscience Partners
    Jafco Life Science
    Bison Capital
    Castle Rock Innovations
  • Series Unknown

    $46,000,000

    Series Unknown Investors

    Burrill & Company
    Advent Venture Partners
    New Enterprise Associates (NEA)
    Academy Venture Fund
    CDIB BioScience Ventures
    Nomura International
    Genavent
    CDC IXIS Innovation
    Easton Capital Investment Group
    Societe Generale Asset Management
    EuclidSR Partners
    Auriga Partners
  • Series Unknown

    $46,000,000

    Series Unknown Investors

    Burrill & Company
    Advent Venture Partners
    New Enterprise Associates (NEA)
    Academy Venture Fund
    CDIB BioScience Ventures
    Nomura International
    Genavent
    CDC IXIS Innovation
    Easton Capital Investment Group
    Societe Generale Asset Management
    EuclidSR Partners
    Auriga Partners
Funding info provided by Diffbot.